CUDC-101 - HDAC/EGFR/HER2 Inhibitor. CAS# 1012054-59-9 Catalog No.:M60092-2S Destabilization of both β-catenin and

Destabilization of both β-catenin and Ras via targeting axin is a potential therapeutic strategy for treatment of CRC and other type cancers activated Wnt/β-catenin and Ras pathways

HLY78 may weaken the autoinhibition of Axin

Shelf Life: ≥12 months if stored properly

Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992)

and CDK1 with IC50 of 35 nM

CUDC-101 - HDAC/EGFR/HER2 Inhibitor. CAS# 1012054-59-9 Catalog No.:M60092-2S Destabilization of both β-catenin andCUDC 101, CAS No. 1012054 59 9, is a potent multi target inhibitor targeting HDAC, EGFR and HER2 with IC50 of 4. 4 nM, 2. 4 nM, and 15. 7 nM, respectively. It is specific for class I and class II HDACs, not for class III Sir type HDACs, and has > 50 fold selectivity against other protein kinases. CUDC 101 displays broad antiproliferative activity in many human cancer cell types with IC50 of 0. 04 0. 80 M, exhibiting a higher potency than erlotinib,